AMENDMENTS TO THE CLAIMS

Claims 1-20 cancelled.

21. (Currently Amended) A pharmacological composition comprising:

(A) at least one biologically-active agent; and

(B) at least one carrier compound having the formula

2-HO-Ar-CONR^8-R^7-COOH

or a salt thereof, wherein

Ar is a phenyl or naphthyl substituted with at least one of C_1-C_5 alkyl, C_2-C_4 alkenyl, -F, -Cl, -OH, -SO_2, -COOH or -SO_3H;

R^7 is selected form the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, phenyl, naphthyl, (C_1 to C_{10} alkyl)phenyl, (C_1 to C_{10} alkenyl)phenyl, (C_1 to C_{10} alkyl)naphthyl, (C_1 to C_{10} alkenyl) naphthyl, phenyl (C_1 to C_{10} alkyl), phenyl (C_1 to C_{10} alkenyl), naphthyl (C_1 to C_{10} alkyl) and naphthyl (C_1 to C_{10} alkenyl);

R^7 is optionally substituted with C_1 to C_4 alkyl, C_1 to C_4 alkenyl, C_1 to C_4 alkoxy, -OH, -SH and -CO_2R^9 or any combination thereof;

R^7 is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof;

R^8 is selected from the group consisting of hydrogen, C_1 to C_4 alkyl, C_1 to C_4 alkenyl, hydroxy, and C_1 to C_4 alkoxy; and

R^8 is optionally substituted with C_1 to C_4 alkyl, C_1 to C_4 alkenyl, C_1 to C_4 alkoxy, -OH, -SH and -CO_2R^9 or any combination thereof;

R^9 is hydrogen, C_1 to C_4 alkyl, or C_1 to C_4 alkenyl;

with the proviso that the compounds are not substituted with an amino group in the position alpha to the acid group.

22. (Currently Amended) The composition of claim 21 wherein Ar is a phenyl substituted ~~phenyl~~ with at least one of C_1-C_5 alkyl, C_2-C_4 alkenyl, -F, -Cl, -OH, $-SO_2$, -COOH or $-SO_3H$.

23. (Original) The composition of claim 21, wherein Ar is a phenyl substituted with -Cl.

24. (Original) The composition of claim 21, wherein Ar is a phenyl substituted with -F.

25. (Currently Amended) The composition of claim 23, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, (C_1-C_{10} alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl).

26. (Original) The composition of claim 23, wherein R^7 is C_4-C_{20} alkyl.

27. (Original) The composition of claim 26, wherein R^7 is not substituted or interrupted.

28. (Original) The composition of claim 27, wherein R^8 is hydrogen.

29. (Previously Presented) The composition of claim 21, wherein the biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid.

30. (Original) The composition of claim 29, wherein the biologically active agent is a peptide.

31. (Original) The composition of claim 29, wherein the biologically active agent is a mucopolysaccharide.

32. (Previously Presented) The composition according to claim 21, wherein the biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, an antimicrobial, an antifungal agent or a combination thereof.

33. (Currently Amended) The composition according to claim 32, wherein said biologically-active agent comprises human growth hormone, an interferon, insulin, heparin, low

molecular weight heparin, calcitonin, erythropoietin, cromolyn sodium, parathyroid hormone, an antimicrobial, an antigen or a combination thereof.

34. (Original) The composition according to claim 33, wherein said biologically-active agent comprises human growth hormone.

35. (Original) The composition according to claim 33, wherein said biologically-active agent comprises insulin.

36. (Original) The composition according to claim 33, wherein said biologically-active agent comprises heparin.

37. (Original) The composition according to claim 33, wherein said biologically-active agent comprises low molecular weight heparin.

38. (Original) The composition according to claim 33, wherein said biologically-active agent comprises calcitonin.

39. (Original) The composition according to claim 33, wherein said biologically-active agent comprises cromolyn sodium.

40. (Original) The composition according to claim 33, wherein said biologically-active agent comprises parathyroid hormone.

41. (Previously Presented) A dosage unit form comprising

(A) a pharmacological composition according to claim 21; and

(B) (i) an excipient,

(ii) a diluent

(iii) a disintegrant

(iv) a lubricant,

(v) a plasticizer,

(vi) a colorant,

(vii) a dosing vehicle, or

(viii) any combination thereof.

42. (Original) The dosage unit form according to claim 41, comprising a tablet, a capsule, or a liquid.

43. (Original) The dosage unit form according to claim 41, wherein said dosing vehicle is selected form the group consisting of water, 1,2-propane diol, ethanol, and any combination thereof.

44. (Currently Amended) A method for preparing a pharmacological composition, said method comprising mixing:

(A) at least one biologically-active agent;

(B) at least one carrier compound having the formula

2OH-Ar-CONR^8-R^7-COOH

wherein

Ar is a ~~substituted~~ phenyl or naphthyl substituted with at least one of C_1-C_5 alkyl, C_2-C_4 alkenyl, -F, -Cl, -OH, -SO_2, -COOH or -SO_3H;

R^7 is selected form the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, phenyl, naphthyl, (C_1 to C_{10} alkyl)phenyl, (C_1 to C_{10} alkenyl)phenyl, (C_1 to C_{10} alkyl)naphthyl, (C_1 to C_{10} alkenyl) naphthyl, phenyl (C_1 to C_{10} alkyl), phenyl (C_1 to C_{10} alkenyl), naphthyl (C_1 to C_{10} alkyl) and naphthyl (C_1 to C_{10} alkenyl);

R^7 is optionally substituted with C_1 to C_4 alkyl, C_1 to C_4 alkenyl, C_1 to C_4 alkoxy, -OH, -SH and -CO_2R^9 or any combination thereof;

R^7 is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof;

R^8 is selected from the group consisting of hydrogen, C_1 to C_4 alkyl, C_1 to C_4 alkenyl, hydroxy, and C_1 to C_4 alkoxy; and

R^9 is hydrogen, C_1 to C_4 alkyl, or C_1 to C_4 alkenyl;

with the proviso that the compounds are not substituted with an amino group in the position alpha to the acid group; and

(C) optionally a dosing vehicle.

45. (Previously Presented) A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 21.

46. (Previously Presented) A method for administering a biologically-active agent to a mammal in need of said agent, said method comprising administering orally to said mammal a composition as defined in claim 21.

47. (New) The composition of claim 21, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, (C_1-C_{10} alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl) and wherein R^8 is hydrogen.

48. (New) The composition of claim 21, wherein R^7 is C_4-C_{20} alkyl and wherein R^8 is hydrogen.

49. (New) The composition of claim 21, wherein R^7 is not substituted or interrupted and wherein R^8 is hydrogen.

50. (New) The composition of claim 21, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, (C_1-C_{10} alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl) and wherein R^8 is C_1-C_4 alkyl.

51. (New) The composition of claim 21, wherein R^7 is C_4-C_{20} alkyl and wherein R^8 is C_1-C_4 alkyl.

52. (New) The composition of claim 21, wherein R^7 is not substituted or interrupted and wherein R^8 is C_1-C_4 alkyl.

53. (New) The composition of claim 21, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, (C_1-C_{10} alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl).

54. (New) The composition of claim 21, wherein R^7 is C_4-C_{20} alkyl.

55. (New) The composition of claim 21, wherein R^7 is not substituted or interrupted.

56. (New) The composition of claim 21, wherein R^8 is hydrogen.

57. (New) The composition of claim 21, wherein R^8 is C_1-C_4 alkyl.

58. (New) The composition of claim 22, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, (C_1-C_{10} alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl) and wherein R^8 is hydrogen..

59. (New) The composition of claim 22, wherein R^7 is C_4-C_{20} alkyl and wherein R^8 is hydrogen.

60. (New) The composition of claim 22, wherein R^7 is not substituted or interrupted and wherein R^8 is hydrogen.

61. (New) The composition of claim 22, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, (C_1-C_{10} alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl) and wherein R^8 is C_1-C_4 alkyl.

62. (New) The composition of claim 22, wherein R^7 is C_4-C_{20} alkyl and wherein R^8 is C_1-C_4 alkyl.

63. (New) The composition of claim 22, wherein R^7 is not substituted or interrupted and wherein R^8 is C_1-C_4 alkyl.

64. (New) The composition of claim 22, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, (C_1-C_{10} alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl).

65. (New) The composition of claim 22, wherein R^7 is C_4-C_{20} alkyl.

66. (New) The composition of claim 22, wherein R^7 is not substituted or interrupted.

67. (New) The composition of claim 22, wherein R^8 is hydrogen.

68. (New) The composition of claim 22, wherein R^8 is C_1-C_4 alkyl.

69. (New) The composition of claim 22, wherein the biologically active agent is a peptide.

70. (New) The composition of claim 22, wherein the biologically active agent is a mucopolysaccharide.

71. (New) The composition of claim 23, wherein R^7 is not substituted or interrupted and wherein R^8 is hydrogen.

72. (New) The composition of claim 23, wherein R^7 is not substituted or interrupted and wherein R^8 is C_1-C_4 alkyl.

73. (New) The composition of claim 23, wherein R^7 is not substituted or interrupted.

74. (New) The composition of claim 23, wherein R^8 is hydrogen.

75. (New) The composition of claim 23, wherein R^8 is C_1-C_4 alkyl.

76. (New) The composition of claim 23, wherein the biologically active agent is a peptide.

77. (New) The composition of claim 23, wherein the biologically active agent is a mucopolysaccharide.

78. (New) The composition of claim 24, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, (C_1-C_{10} alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl) and wherein R^8 is hydrogen..

79. (New) The composition of claim 24, wherein R^7 is C_4-C_{20} alkyl and wherein R^8 is hydrogen.

80. (New) The composition of claim 24, wherein R^7 is not substituted or interrupted and wherein R^8 is hydrogen.

81. (New) The composition of claim 24, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, (C_1-C_{10} alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl) and wherein R^8 is C_1-C_4 alkyl.

82. (New) The composition of claim 24, wherein R^7 is C_4-C_{20} alkyl and wherein R^8 is C_1-C_4 alkyl.

83. (New) The composition of claim 24, wherein R^7 is not substituted or interrupted and wherein R^8 is C_1-C_4 alkyl.

84. (New) The composition of claim 24, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, (C_1-C_{10} alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl).

85. (New) The composition of claim 24, wherein R^7 is C_4-C_{20} alkyl.

86. (New) The composition of claim 24, wherein R^7 is not substituted or interrupted.

87. (New) The composition of claim 24, wherein R^8 is hydrogen.

88. (New) The composition of claim 24, wherein R^8 is C_1-C_4 alkyl.

89. (New) The composition of claim 24, wherein the biologically active agent is a peptide.

90. (New) The composition of claim 24, wherein the biologically active agent is a mucopolysaccharide.

91. (New) The composition of claim 25, wherein R^7 is not substituted or interrupted.

92. (New) The composition of claim 25, wherein R^7 is not substituted or interrupted and wherein R^8 is C_1-C_4 alkyl.

93. (New) The composition of claim 25, wherein R^7 is not substituted or interrupted and wherein R^8 is hydrogen.

94. (New) The composition of claim 25, wherein R^8 is hydrogen.

95. (New) The composition of claim 25, wherein R^8 is C_1-C_4 alkyl.

96. (New) The composition of claim 25, wherein the biologically active agent is a peptide.

97. (New) The composition of claim 25, wherein the biologically active agent is a mucopolysaccharide.

98. (New) The composition of claim 26, wherein R^8 is hydrogen.

99. (New) The composition of claim 26, wherein R^8 is C_1-C_4 alkyl.

100. (New) The composition of claim 26, wherein the biologically active agent is a peptide.

101. (New) The composition of claim 26, wherein the biologically active agent is a mucopolysaccharide.

102. (New) The composition of claim 27, wherein R^8 is C_1-C_4 alkyl.

103. (New) The composition of claim 27, wherein the biologically active agent is a peptide.

104. (New) The composition of claim 27, wherein the biologically active agent is a mucopolysaccharide.

105. (New) The composition of claim 28, wherein the biologically active agent is a peptide.

106. (New) The composition of claim 28, wherein the biologically active agent is a mucopolysaccharide.

107. (New) The composition according to claim 33, wherein said biologically-active agent comprises interferon.

108. (New) The composition according to claim 33, wherein said biologically-active agent comprises erythropoietin.

109. (New) The composition according to claim 33, wherein said biologically-active agent comprises an antigen.

110. (New) The composition according to claim 33, wherein said biologically-active agent comprises an antimicrobial.

111. (New) The dosage unit form according to claim 41, wherein Ar is a phenyl substituted with at least one of C_1-C_5 alkyl, C_2-C_4 alkenyl, -F, -Cl, -OH, -SO_2, -COOH or -SO_3H.

112. (New) The dosage unit form according to claim 41, wherein Ar is a phenyl substituted with -Cl.

113. (New) The dosage unit form according to claim 41, wherein R^8 is hydrogen.

114. (New) The dosage unit form according to claim 41, wherein R^8 is C_1-C_4 alkyl.

115. (New) The dosage unit form according to claim 41, wherein said biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid.

116. (New) The dosage unit form according to claim 41, wherein said biologically active agent is a peptide.

117. (New) The dosage unit form according to claim 41, wherein said biologically active agent is a mucopolysaccharide.

118. (New) The dosage unit form according to claim 41, wherein said biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low

molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, an antimicrobial, an antifungal agent or a combination thereof.

119. (New) The dosage unit form according to claim 41, wherein Ar is a phenyl substituted with -F.

120. (New) The dosage unit form according to claim 41, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, (C_1-C_{10} alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl).

121. (New) The dosage unit form according to claim 41, wherein R^7 is C_4-C_{20} alkyl.

122. (New) The dosage unit form according to claim 41, wherein R^7 is not substituted or interrupted.

123. (New) The dosage unit form according to claim 41, comprising a tablet.

124. (New) The dosage unit form according to claim 41, comprising a capsule.

125. (New) The method according to claim 44, wherein the biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid.

126. (New) The method according to claim 44, wherein the biologically active agent is a peptide.

127. (New) The method according to claim 44, wherein the biologically active agent is a mucopolysaccharide.

128. (New) The method according to claim 44, wherein the biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, an antimicrobial, an antifungal agent or a combination thereof.

129. (New) The method according to claim 44, wherein said biologically-active agent comprises human growth hormone, an interferon, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, cromolyn sodium, parathyroid hormone, an antimicrobial or a combination thereof.

130. (New) The method according to claim 44, wherein said biologically-active agent comprises human growth hormone.

131. (New) The method according to claim 44, wherein said biologically-active agent comprises insulin.

132. (New) The method according to claim 44, wherein said biologically-active agent comprises heparin.

133. (New) The method according to claim 44, wherein said biologically-active agent comprises low molecular weight heparin.

134. (New) The method according to claim 44, wherein said biologically-active agent comprises calcitonin.

135. (New) The method according to claim 44, wherein said biologically-active agent comprises cromolyn sodium.

136. (New) The method according to claim 44, wherein said biologically-active agent comprises parathyroid hormone.

137. (New) The method according to claim 44, wherein said biologically-active agent comprises interferon.

138. (New) The method according to claim 44, wherein said biologically-active agent comprises erythropoietin.

139. (New) The method according to claim 44, wherein said biologically-active agent comprises an antigen.

140. (New) The method according to claim 44, wherein said biologically-active agent comprises an antimicrobial.

141. (New) The method according to claim 44, wherein Ar is a phenyl substituted with at least one of C_1-C_5 alkyl, C_2-C_4 alkenyl, -F, -Cl, -OH, $-SO_2$, -COOH or $-SO_3H$.

142. (New) The method according to claim 44, wherein Ar is a phenyl substituted with -Cl.

143. (New) The method according to claim 44, wherein Ar is a phenyl substituted with -F.

144. (New) The method according to claim 44, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, (C_1-C_{10} alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl).

145. (New) The method according to claim 44, wherein R^7 is C_4-C_{20} alkyl.

146. (New) The method according to claim 44, wherein R^7 is not substituted or interrupted.

147. (New) The method according to claim 44, wherein R^8 is hydrogen.

148. (New) The method according to claim 44, wherein R^8 is C_1-C_4 alkyl.

149. (New) The method according to claim 45, wherein the biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid.

150. (New) The method according to claim 45, wherein the biologically active agent is a peptide.

151. (New) The method according to claim 45, wherein the biologically active agent is a mucopolysaccharide.

152. (New) The method according to claim 45, wherein the biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, an antimicrobial, an antifungal agent or a combination thereof.

153. (New) The method according to claim 45, wherein said biologically-active agent comprises human growth hormone, an interferon, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, cromolyn sodium, parathyroid hormone, an antimicrobial or a combination thereof.

154. (New) The method according to claim 45, wherein said biologically-active agent comprises human growth hormone.

155. (New) The method according to claim 45, wherein said biologically-active agent comprises insulin.

156. (New) The method according to claim 45, wherein said biologically-active agent comprises heparin.

157. (New) The method according to claim 45, wherein said biologically-active agent comprises low molecular weight heparin.

158. (New) The method according to claim 45, wherein said biologically-active agent comprises calcitonin.

159. (New) The method according to claim 45, wherein said biologically-active agent comprises cromolyn sodium.

160. (New) The method according to claim 45, wherein said biologically-active agent comprises parathyroid hormone.

161. (New) The method according to claim 45, wherein said biologically-active agent comprises interferon.

162. (New) The method according to claim 45, wherein said biologically-active agent comprises erythropoietin.

163. (New) The method according to claim 45, wherein said biologically-active agent comprises an antigen.

164. (New) The method according to claim 45, wherein said biologically-active agent comprises an antimicrobial.

165. (New) The method according to claim 45 wherein Ar is a phenyl substituted with at least one of C_1-C_5 alkyl, C_2-C_4 alkenyl, -F, -Cl, -OH, $-SO_2$, -COOH or -SO_3H.

166. (New) The method according to claim 45, wherein Ar is a phenyl substituted with –Cl.

167. (New) The method according to claim 45, wherein Ar is a phenyl substituted with –F.

168. (New) The method according to claim 45, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl (C_1-C_{10} alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl).

169. (New) The method according to claim 45, wherein R^7 is C_4-C_{20} alkyl.

170. (New) The method according to claim 45, wherein R^7 is not substituted or interrupted.

171. (New) The method according to claim 45, wherein R^8 is hydrogen.

172. (New) The method according to claim 45, wherein R^8 is C_1-C_4 alkyl.

173. (New) The method according to claim 46, wherein the biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid.

174. (New) The method according to claim 46, wherein the biologically active agent is a peptide.

175. (New) The method according to claim 46, wherein the biologically active agent is a mucopolysaccharide.

176. (New) The method according to claim 46, wherein the biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin,

vasopressin, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, an antimicrobial, an antifungal agent or a combination thereof.

177. (New) The method according to claim 46, wherein said biologically-active agent comprises human growth hormone, an interferon, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, cromolyn sodium, parathyroid hormone, an antimicrobial or a combination thereof.

178. (New) The method according to claim 46, wherein said biologically-active agent comprises human growth hormone.

179. (New) The method according to claim 46, wherein said biologically-active agent comprises insulin.

180. (New) The method according to claim 46, wherein said biologically-active agent comprises heparin.

181. (New) The method according to claim 46, wherein said biologically-active agent comprises low molecular weight heparin.

182. (New) The method according to claim 46, wherein said biologically-active agent comprises calcitonin.

183. (New) The method according to claim 46, wherein said biologically-active agent comprises cromolyn sodium.

184. (New) The method according to claim 46, wherein said biologically-active agent comprises parathyroid hormone.

185. (New) The method according to claim 46, wherein said biologically-active agent comprises interferon.

186. (New) The method according to claim 46, wherein said biologically-active agent comprises erythropoietin.

187. (New) The method according to claim 46, wherein said biologically-active agent comprises an antigen.

188. (New) The method according to claim 46, wherein said biologically-active agent comprises an antimicrobial.

189. (New) The method according to claim 46 wherein Ar is a phenyl substituted with at least one of C_1-C_5 alkyl, C_2-C_4 alkenyl, -F, -Cl, -OH, -SO_2, -COOH or -SO_3H.

190. (New) The method according to claim 46, wherein Ar is a phenyl substituted with -Cl.

191. (New) The method according to claim 46, wherein Ar is a phenyl substituted with -F.

192. (New) The method according to claim 46, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl (C_1-C_{10} alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl).

193. (New) The method according to claim 46, wherein R^7 is C_4-C_{20} alkyl.

194. (New) The method according to claim 46, wherein R^7 is not substituted or interrupted.

195. (New) The method according to claim 46, wherein R^8 is hydrogen.

196. (New) The method according to claim 46, wherein R^8 is C_1-C_4 alkyl.

197. (New) A method for administering a biologically-active agent to a human in need of said agent, said method comprising administering orally to said human a composition as defined in claim 21.

198. (New) The method according to claim 197, wherein the biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid.

199. (New) The method according to claim 197, wherein the biologically active agent is a peptide.

200. (New) The method according to claim 197, wherein the biologically active agent is a mucopolysaccharide.

201. (New) The method according to claim 197, wherein the biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, an antimicrobial, an antifungal agent or a combination thereof.

202. (New) The method according to claim 197, wherein said biologically-active agent comprises human growth hormone, an interferon, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, cromolyn sodium, parathyroid hormone, an antimicrobial or a combination thereof.

203. (New) The method according to claim 197, wherein said biologically-active agent comprises human growth hormone.

204. (New) The method according to claim 197, wherein said biologically-active agent comprises insulin.

205. (New) The method according to claim 197, wherein said biologically-active agent comprises heparin.

206. (New) The method according to claim 197, wherein said biologically-active agent comprises low molecular weight heparin.

207. (New) The method according to claim 197, wherein said biologically-active agent comprises calcitonin.

208. (New) The method according to claim 197, wherein said biologically-active agent comprises cromolyn sodium.

209. (New) The method according to claim 197, wherein said biologically-active agent comprises parathyroid hormone.

210. (New) The method according to claim 197, wherein said biologically-active agent comprises interferon.

211. (New) The method according to claim 197, wherein said biologically-active agent comprises erythropoietin.

212. (New) The method according to claim 197, wherein said biologically-active agent comprises an antigen.

213. (New) The method according to claim 197, wherein said biologically-active agent comprises an antimicrobial.

214. (New) The method according to claim 197 wherein Ar is a phenyl substituted with at least one of C_1-C_5 alkyl, C_2-C_4 alkenyl, -F, -Cl, -OH, $-SO_2$, -COOH or -SO_3H.

215. (New) The method according to claim 197, wherein Ar is a phenyl substituted with -Cl.

216. (New) The method according to claim 197, wherein Ar is a phenyl substituted with -F.

217. (New) The method according to claim 197, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, (C_1-C_{10} alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl).

218. (New) The method according to claim 197, wherein R^7 is C_4-C_{20} alkyl.

219. (New) The method according to claim 197, wherein R^7 is not substituted or interrupted.

220. (New) The method according to claim 197, wherein R^8 is hydrogen.

221. (New) The method according to claim 197, wherein R^8 is C_1-C_4 alkyl.